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ABSTRAK 
TAJUK: 
PEMBERIAN BOLUS INTRAVENOUS UBAT TRANEXAMIC ACID DIIKUTI OLEH 
PEMBERIAN SECARA INTRAVENENOUS INFUSI SERTA PENGAWALAN KETAT 
TEKANAN DARAH BAGI RAWATAN PENYAKIT STROK JENIS PENDARAHAN 
OTAK 
 
PENGENALAN 
Pendarahan spontan dalam otak  merangkumi 10-15% daripada kes strok dengan insidens 10-30 
kes per 100 000 orang setiap tahun dan dijangka akan meningkat 2 kali ganda dalam tempoh 30 
tahun akan datang. Mortaliti dan morbiditi yang terkait dengan perdarahan spontan dalam otak 
masih tinggi. Sehingga kini masih tiada rawatan yang terbukti efektif untuk pendarahan spontan 
dalam otak.  Faktor penting untuk meramal prognosis pesakit adalah pertambahan saiz 
hematoma. Tranexamic Acid (TXA) adalah ubat anti- fibrinolisis yang berkesan dalam 
mengurangkan pendarahan. Kajian ini adalah untuk menilai keberkesanan tranexamic asid 
berbanding placebo dalam menghalang pertambahan saiz pendarahan pada pesakit dengan 
pendarahan dalam otak    
METODOLOGI 
Dalam penyelidikan, a single blinded, randomized placebo-controlled trial. Labetolol digunakan 
untuk mencapai target sistolik tekanan darah 140-160 mmHg. Imbasan Otak (CT Brain) 
16 
 
dilakukan dalam tempoh 24 jam untuk menilai perubahan saiz hematoma. Objektif utama kajian 
ini adalah untuk menguji kesan tranexamic acid terhadap perubahan saiz pendarahan. Objektif 
lain yang ingin dicapai dengan kajian ini adalah menguji pelaksanaan dan kesan sampingan TXA 
ini terhadap pendarahan spontan dalam otak. 
KEPUTUSAN 
Seramai 30 orang pesakit direkrut dalam tempoh dari September 2012 dan Oktober 2013. Mean 
umur 45 tahun, dengan predominan lelaki (70%), paras tekanan darah sistolik 150 mmHg, mean 
skor kesedaran (GCS 13/15), median masa dari serangan stroke kepada perawakan (5.5 jam), 
masa dari perawakan kepada rawatan (20 minit) lokasi hematoma  ( internal capsule 80%, 
thalamus 13.3% dan head of caudate 6.66%). Mean pertambahan saiz hematoma adalah 0.16 ml 
dan 3.07mls masing- masing pada kumpulan yang diberikan TXA dan placebo. Analisis statistik 
menunjukan penurunan dalam  peningkatan saiz hematoma dalam kumpulan TXA berbanding 
kumpulan placebo (p<0.5) 
 
KESIMPULAN 
Pesakit yang hadir dengan pendarahan dalam otak secara spontan  akibat dari tekanan darah yang 
tidak terkawal yang mana tidak memerlukan pembedahan harus diberikan kombinasi rawatan 
dengan pemberian bolus ubat tranexamic acid 1 gram diiringi dengan dos infusi 1g / 8jam serta 
mengawal secara ketat bacaan tekanan darah dibandingan dengan pengawalan tekanan darah 
sahaja. Namun, kajian perawakan berganda harus dilakukan dengan melibatan pelbagai pusat 
rawat untuk tujuan evaluasi yang lebih signifikan. 
17 
 
 
ABSTRACT 
Title 
THE BOLUS ADMINISTRATION OF TRANEXAMIC ACID WITH A MAINTENANCE 
DOSE VIA INFUSION AND STRICT BLOOD PRESSURE CONTROL FOR NON-
TRAUMATIC INTRACEREBRAL HEMORRHAGES 
Introduction 
Spontaneous intracerebral hemorrhages (ICH) account for 10–15% of all strokes with an 
incidence of 10–30 cases per 100,000 people/year, and their incidences are expected to double in 
the next 30 years. Mortality and morbidity associated with ICHs is still high. Until recently, there 
were no effective evidence-based treatments for acute ICH. ICH growth remains an important 
predictor of patient outcomes. Tranexamic acid (TXA), an anti-fibrinolytic drug, is known to 
reduce hemorrhaging in other conditions. The purpose of this study was to assess the effect of 
TXA compared to a placebo on the growth of hematomas in patients with spontaneous ICH. 
Methodology 
A single-blinded randomized placebo-controlled trial was conducted using TXA (intravenous 1 g 
bolus followed by an infusion of TXA at 1g/h for 8 h) in acute (<8 h) cases of primary ICH. 
Strict blood pressure control (target systolic blood pressure [SBP], 140–160 mmHg) was 
achieved using labetalol infusion. A repeat brain computed tomography (CT) was performed in 
the next 24 h to reassess the hematoma growth. The primary objective was to test the effect of 
TXA on hematoma growth. The secondary objective was to test the feasibility, tolerability, and 
adverse events of TXA in cases of primary ICH.  
18 
 
 
Results 
Thirty patients were recruited between September 2012 and October 2013. The patients’ mean 
age was 49 with male predominance (70%). The baseline SBP was 150 mmHg), mean Glasgow 
Coma Scale score was 13–15/15), and median time from stroke to the 1st CT scan was 5.5 h. The 
hematoma locations were as follows: internal capsule, 80%; thalamus, 13.3%; and head of 
caudate, 6.66%. The mean total hemorrhage growth was 0.16 mL and 3.07 mL in the treatment 
and placebo groups, respectively. Statistical analysis showed a reduction in the total hemorrhage 
growth in the TXA group in comparison to the control (p < 0.05). 
 
Conclusions 
Patients who present with spontaneous ICH secondary to uncontrolled hypertension should be 
treated with a combination of a bolus administration of TXA (1 g) and a maintenance dose via 
infusion (1 g/8 h) with strict blood pressure control, rather than blood pressure control alone. 
However, a double-blinded randomized study with multicenter involvement is needed for further 
evaluation of the significance of this finding.  
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1.0 INTRODUCTION 
1.1 Incidence  
Spontaneous, non-traumatic intracerebral hemorrhages (ICH) are a significant cause of morbidity 
and mortality worldwide. Despite substantial advances in neurovascular critical care, ICH 
remains the deadliest form of stroke and a major cause of neurological disability. Studies 
indicate that the proportion of ICH is higher in Asians than in Caucasians, with approximately 
20–30% of ICH cases being hemorrhagic (van Asch et al. 2010). 
Expansion of the initial hematoma strongly influences morbidity and mortality. The hazard ratio 
of mortality increases by 5%, with every 10% increase in ICH volume. In addition, each absolute 
increase in volume (mL) causes patient outcomes to be 7% more likely to shift from 
independence to dependence, as measured by the six-point modified Rankin Scale. Numerous 
other studies confirm the relationship of the hematoma expansion with neurological deterioration, 
poor functional outcome, and death. These relationships appear to be independent from the 
definition used for hematoma expansion. Moreover, data from the INTERACT 1 trial suggest a 
clear dose-response relationship between the magnitude of hematoma expansion and functional 
outcome and mortality, when using either the absolute or proportional definitions of expansion. 
Outcome 
To date, no individual treatment for ICH has shown a benefit in a randomized controlled trial, 
although specialized treatment provided at a neuroscience intensive-care unit (ICU) did appear to 
reduce mortality. Because of its strong relationship with outcomes and the potential to alter its 
course, hematoma expansion is an appealing therapeutic target. Candidate treatments aimed at 
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improving ICH outcomes potentially reduce hematoma expansion. However, mortality and 
morbidity rates associated with ICHs are still high. Until recently, there have been no effective 
evidence-based treatments for acute ICH. Thus, ICH growth remains an important predictor of 
patient outcome. 
2 LITERATURE REVIEW 
2.1 Spontaneous intracerebral hemorrhage 
ICHs are an important public health problem associated with high rates of death and disability in 
adults. Although the number of hospital admissions for ICH has increased worldwide in the past 
10 years, mortality rate has not decreased. The results of clinical trials and observational studies 
suggest that coordinated primary and specialty care is associated with a lower mortality than 
typical community practice (Gregson et al. 2010). 
Development of treatment goals for critical care and new sequences of care and specialty 
practice can improve outcomes after ICH. Specific treatment approaches include early diagnosis 
and hemostasis, aggressive management of blood pressure, open and minimally invasive surgical 
techniques to remove clots, techniques for removing intraventricular blood, and management of 
intracranial pressure. These approaches improve the clinical management of ICH patients, reduce 
mortality, and increase functional survival (Morgenstern 2010). 
 
2.2 Introduction 
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Non-traumatic ICH results from the rupture of blood vessels in the brain. It is a major public 
health problem with an annual incidence of 10–30 per 100,000 population, accounting for 2 
million (10–15%) of about 15 million strokes worldwide each year (Morgenstern 2010). Hospital 
admissions for ICHs have increased by 18% in the past 10 years, which is probably because of 
the increase in the number of elderly people, many of whom lack adequate blood pressure 
control and increasingly use anticoagulants, thrombolytics, and antiplatelet agents. Mexican 
Americans, Latin Americans, African Americans, Native Americans, Japanese, and Chinese 
have higher incidences of ICH than white Americans (van Asch et al. 2010). These differences 
are mostly seen in the incidence of deep ICH and are most prominent in young and middle-aged 
people. The incidence may be decreased in some populations with improved access to medical 
care and blood pressure control
 
(van Asch et al. 2010).  
Primary and secondary (anticoagulant-induced) ICHs have similar underlying pathological 
changes (Huhtakangas et al. 2011).
 
ICH commonly affects the cerebral lobes, basal ganglia, 
thalamus, brain stem (predominantly the pons), and cerebellum because of the ruptured vessels 
due to the hypertension-related degenerative changes or cerebral amyloid angiopathy
 
(Viswanathan et al. 2011). Most bleeding in hypertension-related ICH is at or near the 
bifurcation of small penetrating arteries that originate from the basilar arteries or the anterior, 
middle, or posterior cerebral arteries. Small artery branches of 50–700 μm in diameter often have 
multiple sites of rupture; some are associated with layers of platelet and fibrin aggregates. These 
lesions are characterized by breakage of elastic lamina, atrophy and fragmentation of smooth 
muscles, dissections, and granular or vesicular cellular degeneration. In particular, severe 
atherosclerosis, including lipid deposition, can affect elderly patients. Fibrinoid necrosis of the 
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subendothelium with subsequent focal dilatations (i.e., micro-aneurysms) leads to ruptures in a 
small proportion of patients (Takebayashi et al. 2012). 
Cerebral amyloid angiopathy is characterized by the deposition of amyloid-β peptide and 
degenerative changes (e.g., micro-aneurysm formation, concentric splitting, chronic 
inflammatory infiltrates, and fibrinoid necrosis) in the capillaries, arterioles, and small- and 
medium-sized arteries of the cerebral cortex, leptomeninges, and cerebellum (Rosand et al. 2009). 
Cerebral amyloid angiopathy leads to sporadic ICH in elderly people, which is commonly 
associated with variations in the gene encoding apolipoprotein E, and a familial syndrome in 
young patients is typically associated with mutations in the gene encoding amyloid precursor 
protein (Rost NS 2008). White matter abnormalities (e.g., leukoaraiosis) seem to increase the 
risk of sporadic and familial ICHs, suggesting a shared vascular pathogenesis
 
(Hart & Smith 
2004).  
ICH associated with oral anticoagulants typically affects patients with vasculopathies related to 
either chronic hypertension or cerebral amyloid angiopathy, which may represent an 
exacerbation of an existing risk of a clinical or subclinical disease (Viswanathan et al. 2011). 
2.3 Pathophysiology 
Regions surrounding hematomas are characterized by edema, apoptosis, necrosis, and 
inflammatory cells. Hematomas induce injury (Figure 2.3) by causing a mechanical disruption of 
the neurons and glia, followed by mechanical deformation that causes oligemia, neurotransmitter 
release, mitochondrial dysfunction, and membrane depolarization (Pérez et al. 2010). 
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Dependent on the severity of mitochondrial dysfunction, the results of injury range from 
temporary metabolic suppression (i.e., a hibernation phase) to cellular swelling and necrosis. A 
secondary cascade of injury is caused by the products of coagulation and hemoglobin breakdown, 
in particular thrombin, which activates microglia within 4 h after injury (Wu et al. 2013). 
Activated microglia release products that induce the breakdown of the blood-brain barrier, 
vasogenic edema, and apoptosis in the neurons and glia
 
(Pérez et al. 2010). 
 
 Figure 2.3: The cascade of neural injury initiated by intracerebral hemorrhages (Qureshi et 
al. 2009) 
 
Hemostasis is initiated by the local activation of hemostatic pathways and mechanical tamponade. 
However, about 73% of patients assessed within 3 h of symptom onset have some degree of 
hematoma enlargement, and up to 35% have clinically prominent enlargement (Qureshi et al. 
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2014). Most hematoma enlargement occurs within 3 h after injury, although enlargement can 
occur up to 12 h after onset. Perihematomal edema increases in volume by about 75% in the first 
24 h after ICH, peaking within 5–6 days and lasting up to 14 days (AI Qureshi et al. 2009). An 
early large edema volume relative to the hematoma volume has the greatest effect on outcome. 
However, even an edema that is small initially can increase in volume in the first 24 h after 
hemorrhage. An acute hypometabolic and hypoperfusion (hibernation) phase with mitochondrial 
dysfunction and metabolic failure has been reported in the region surrounding the hematoma 
(Qureshi et al. 2009) (Figure 2.3.i). 
Regional hypoperfusion in clinical and experimental studies does not always seem severe enough 
to induce ischemia, and it may be secondary to hypometabolism. In the presence of very high 
intracranial pressure and low cerebral perfusion pressure, the risk of global ischemia is high. A 
variable reperfusion phase lasts from 2–14 days, and a normalization phase develops after 14 
days with the re-establishment of normal cerebral blood flow in all viable regions (Kwon 2014 & 
Greenberg 2009). 
 
